Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
75 hedge funds and large institutions have $84.3M invested in Cascadian Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 22 closing their positions.
71% more call options, than puts
Call options by funds: $94K | Put options by funds: $55K
17% more capital invested
Capital invested by funds: $72M → $84.3M (+$12.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 80 → 75 (-5)
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$28.3M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$12.2M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$1.9M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$1.7M |
| 5 |
Millennium Management
New York
|
+$721K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.48M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.77M |
| 3 |
GCM
Gruss Capital Management
New York
|
-$1.41M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.01M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$902K |
CASC Hedge Fund Activity: Q2 2016 in Review
75 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q2 2016, worth a combined $84.3M — up 17% from $72M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CASC and 18 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 17 added.
The largest buyer was Baupost Group, opening a new position worth an estimated $28.3M. The largest seller was BlackRock Fund Advisors, cutting an estimated $2.48M.
- 75 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q2 2016, down from 80 in Q1 2016.
- Funds reported $84.3M of Cascadian Therapeutics, Inc. stock for Q2 2016, up 17% quarter-over-quarter.
- 18 funds opened new Cascadian Therapeutics, Inc. positions in Q2 2016 and 22 closed out, a net change of -4 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q2 2016 was Baupost Group, an estimated $28.3M added.
- The largest Cascadian Therapeutics, Inc. seller in Q2 2016 was BlackRock Fund Advisors, an estimated $2.48M sold.
Based on aggregated 13F filings for Q2 2016.